The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated

Inicure was pitched by CEO Peter Olofsson-Sahl at GoWest – Nordic capital 28-29 January 2026. Inicures approach to

Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of

Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several

Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at

CEO, Peter Olofsson-Sahl presented Inicure at the #BiotechHanse event as innovative Swedish Life Science innovation for Sweden-Germany collaboration